Phaseline

Companies › Debiopharm International

Debiopharm International: clinical trials, targets and expected readouts

8 active drug programs in 10 registered trials: 8 Phase 1, 2 Phase 3; Oncology, Metabolic and endocrine, Other, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Debio 4326
GnRH receptor agonist
GNRH1Phase 3Central Precocious PubertyFeb 2028
Debio 4126
somatostatin analog (somatostatin receptor agonist)
SSTR2, SSTR5Phase 3AcromegalyJun 2028
Debio 1453P–Phase 1Healthy ParticipantsNov 2026
Afabicin
Enoyl-[acyl-carrier-protein] reductase (FabI) inhibitor
–Phase 1Renal ImpairmentDec 2027
Lunresertib
PKMYT1 inhibitor
PKMYT1Phase 1Advanced Solid TumorDec 2027
RP-3500
ATR inhibitor
ATRPhase 1Advanced Solid Tumor; Solid TumorDec 2027
Zedoresertib (Debio 0123)–Phase 1Advanced Solid Tumor; Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeDec 2027
Debio 1562M–Phase 1Acute Myeloid LeukemiaNov 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05566574RP-3500Phase 1Solid TumorOncologySep 2026
NCT07035769Debio 1453PPhase 1Healthy ParticipantsOtherNov 2026
NCT07758608AfabicinPhase 1Renal ImpairmentGenitourinaryDec 2027
NCT04855656LunresertibPhase 1Advanced Solid TumorOncologyDec 2027
NCT04855656RP-3500Phase 1Advanced Solid TumorOncologyDec 2027
NCT04855656Zedoresertib (Debio 0123)Phase 1Advanced Solid TumorOncologyDec 2027
NCT06129539Debio 4326Phase 3Central Precocious PubertyMetabolic and endocrineFeb 2028
NCT06930625Debio 4126Phase 3AcromegalyMetabolic and endocrineJun 2028
NCT05765812Zedoresertib (Debio 0123)Phase 1Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeOncologySep 2028
NCT06969430Debio 1562MPhase 1Acute Myeloid LeukemiaOncologyNov 2031

Targets

GNRH1 (1) PKMYT1 (1) ATR (1) SSTR2 (1) SSTR5 (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio ITM Solucin Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology RECORDATI GROUP Tolmar AstraZeneca

Companies built like this

Crinetics Pharmaceuticals Kyowa Kirin RayzeBio Shandong Boan Biotechnology Nuvalent

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.